Study information for participants: Investigating a potential new treatment for Vitiligo.
Quick Reference:
What is the purpose of this study?
Where is my nearest study site?
What is the purpose of this study?
This study aims to evaluate the effectiveness of the FB102 antibody in treatment of Vitiligo and associated conditions.
Where is my nearest study site?
Here is a list of all of the sites who are currently recruiting for this study:
Queensland
- Veracity Clinical Research -
Suite 18, Level 1/250 Ipswich Rd, Woolloongabba QLD 4102 - Cornerstone Dermatology -
346 Old Cleveland Rd, Coorparoo QLD 4151
New South Wales
- Novatrials -
Level 1/10 Bradford Cl, Kotara NSW 2289 - The Skin Hospital Darlinghurst -
121 Crown St, Darlinghurst NSW 2010
New Zealand
- Optimal Central Auckland -
Level 2, 97 Grafton Road, Grafton 1010 - Optimal North Auckland -
Unit 5B, 74-76 Paul Matthews Road, Rosedale 632 - PCRN Wellington -
Lakeland Clinical Trials Wellington , Queen Street Ebdentown, Wellington 5018 - Momentum Pukekohe -
6 Roulston Street, Pukekohe 2120, New Zealand
Who can participate?
To take part in this study, you will need to meet all the following:
- Males and females aged ≥ 18 to 65 years at time of screening.
- Highly effective contraception or equivalent.
- Must meet particular vitiligo criteria at time of screening.
- Medications must be at a stable dose.
Who cannot participate?
Unfortunately, you will not be able to participate if:
- Currently have active forms of other hypopigmentation
- Currently have active forms of inflammatory skin disease(s) or evidence of skin conditions
- You have received certain vitiligo treatments recently
- History of treatment failure for vitiligo
- You have a medical condition that might interfere with study participation
Additional exclusion criteria apply.
What is involved?
If you are deemed eligible for the study, your participation is expected to last approximately 30 weeks. This includes:
- pre screening up to 28 days (1 visit)
- 10 additional visits to site (spread over 26 weeks)
Participation in this research is voluntary, and you may withdraw from the study at any time.
If you take part in the research study, there will be:
- Reimbursement of costs; For out-of-pocket expenses, such as travel and parking.
- Convenience; There are no overnight stays.
- Free study-related medical care; Be among the first to access potential new research treatments before they are widely available.
- Expert medical monitoring; Receive top-tier medical care and monitoring from experienced healthcare professionals.
- Contribution to medical research; Help investigate a potential new treatment that could improve the lives of individuals with vitiligo.
What is Vitiligo?
Vitiligo is a skin condition that causes loss of pigmentation, resulting in white patches on the skin. It occurs when the immune system attacks pigment-producing cells called melanocytes. The condition can affect self-esteem and quality of life, making effective treatments important
Why is this study important?
This study is important as Vitiligo can lead to other autoimmune diseases which affect quality of life and increases the need for healthcare, treatment could prevent this.
Who is involved?
This study is being sponsored by Forte Biosciences Australia Pty Ltd
This trial has been approved by an independent ethics committee
Ready to register? Click here to sign up/login to Evrilink and start your clinical trial journey.
Still have questions? Use the form below and one of our patient experience team members will be in touch to assist with your enquiry!